Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer: Advanced Disease

Join Jae Kim, MD and Karen Reckamp, MD from City of Hope Comprehensive Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to advanced disease lung cancer.

The NCCN Guidelines recommend a multidisciplinary approach for patients with non-small cell lung cancer (NSCLC) so that treatment can be tailored for individual patients, which will improve outcomes by decreasing toxicity and increasing quality of life. Most patients with NSCLC have advanced disease at diagnosis and are candidates for systemic therapy. Before recommending therapy, it is essential to determine both the histology of the tumor and whether the patient has specific genetic alterations, such as sensitizing EGFR mutations or ALK rearrangements, and thus would be eligible for targeted therapy.  Recent randomized trials have shown that targeted therapy improves outcomes by decreasing dyspnea, pain, and cough when compared with chemotherapy for select patients eligible for targeted therapy. In addition, targeted therapy is often associated with fewer adverse events than chemotherapy. However, a few patients may have unique side effects from targeted therapy; therefore, patients need to be carefully monitored. The number of available targeted agents for NSCLC is increasing, and many are in clinical trials. New targeted agents have recently been approved such as afatinib and ceritinib. For patients without genetic alterations, systemic chemotherapy is recommended. A recent phase III randomized trial showed that ramucirumab/docetaxel improved overall survival when compared with docetaxel alone in patients with NSCLC who have progressed on platinum-based therapy. Recent data suggest that immunotherapy may be useful for patients with advanced NSCLC and many agents are in clinical trials. Oncologists need to be aware of the most recent updates about treatment with systemic agents, including how to sequence the different agents, so they can effectively manage their patients with advanced NSCLC.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Compare the pros and cons of the targeted therapies for the treatment of advanced non-small cell lung cancer
  • Discuss how to sequence therapy for patients with advanced non-small cell lung cancer
Additional information
Supporters: 

This activity is supported by educational grants from:

  • BTG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Genomic Health, Inc.
  • Lilly
  • Merck
  • Novartis Oncology
  • Prometheus Laboratories, Inc.
  • Spectrum Pharmaceuticals, Inc.

This activity is supported by a grant from AstraZeneca.

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 0.95 ANCC contact hours
  • 1.00 Participation
Course opens: 
03/18/2016
Course expires: 
03/18/2017
Cost:
$0.00
Part of: 
Archived Monthly Oncology Tumor Boards (June 2015 - June 2016)

Jae Kim, MD
City of Hope Comprehensive Cancer Center

Karen Reckamp, MD
City of Hope Comprehensive Cancer Center

 

Disclosure of Relevant Financial Relationships

All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Faculty Disclosures
The faculty listed below have disclosed the following relevant financial relationships:

Karen Reckamp, MD
Adaptimmune – Grant/Research Support
Amgen – Consulting Fees
ARIAD Pharmaceuticals – Consulting Fees; Grant/Research Support
Astellas – Consulting Fees
Boehringer Ingelheim – Consulting Fees; Grant/Research Support
Bristol Myers Squibb –Grant/Research Support
Clovis – Grant/Research Support
Eisai Inc – Grant/Research Support
Nektar – Consulting Fees
Novartis Pharmaceuticals Corporation  – Grant/Research Support
Pfizer – Grant/Research Support
Xcovery – Grant/Research Support

The faculty listed below have no relevant financial relationships to disclose:

Jae Kim, MD

NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:

Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no financial relationships to disclose:

Miranda Hughes, MD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.95 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge

National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-16-014-H01-P

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 0.95 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing